Cingolani, A;
Lepri, AC;
Teofili, L;
Galli, L;
Mazzotta, V;
Baldin, GM;
Hohaus, S;
... Antinori, A; + view all
(2017)
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population.
PLoS ONE
, 12
(10)
, Article e0186549. 10.1371/journal.pone.0186549.
Preview |
Text
journal.pone.0186549.pdf - Published Version Download (1MB) | Preview |
Abstract
OBJECTIVES: to compare overall survival in HIV-associated lymphoma (HIV-L) and lymphoma raising in HIV-negative population (nHIV-L) and to identify predictors of increased risk of death. METHODS: All HIV+ patients with HIV-associated lymphoma (Hodgkin lymphoma, HL; non-Hodgkin Lymphoma, NHL) observed between 1.2000 and 12.2013 in the ICONA Foundation Study cohort or in three collaborating centres, and, as control group, nHIV-L individuals followed in one of the four collaborating centres over the same time period, were included. Survival estimates were calculated by use of Kaplan-Meier (KM) and multivariable Cox regression models. RESULTS: 1,331 pts were included (465 HIV-L, 866 nHIV-L): 909 (68%) NHL, 422 (32%) HL. 3 years-cumulative probability (95% confidence interval, CI) of death was higher in HIV-L compared to nHIV-L in NHL (38% (33–44) vs. 22% (19–26); p<0.001), and HL (22% [15–29] vs. 10% (6–13), p<0.001). Among HL, HIV was associated with an increased risk of death (hazard ratio [HR] = 2.37 [95% CI: 1.24–4.55], p = 0.009) independently of calendar year, age, gender, type of chemotherapy and stage; in NHL, HIV was no longer an independent predictor of death after controlling for rituximab use and IPI (HR = 1.26 (0.97–1.63), p = 0.08). CONCLUSIONS: Our analysis shows a reduced overall survival in HIV+ patients diagnosed with lymphoma compared to HIV-negative controls. Whereas in HIV people with HL, the increased risk of death was confirmed even after adjustment for main confounders, the association between HIV status and survival in NHL appears to be somewhat attenuated after controlling for more aggressive presentation and lower frequency of rituximab use in HIV-+ people.
| Type: | Article |
|---|---|
| Title: | Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0186549 |
| Publisher version: | http://doi.org/10.1371/journal.pone.0186549 |
| Language: | English |
| Additional information: | © 2017 Cingolani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Keywords: | Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, ACTIVE ANTIRETROVIRAL THERAPY, B-CELL LYMPHOMA, CHEMOTHERAPY PLUS RITUXIMAB, AIDS-RELATED LYMPHOMA, NON-HODGKIN-LYMPHOMA, CART ERA, OUTCOMES, COHORT, CHOP, TRENDS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10038818 |
Archive Staff Only
 |
View Item |
